Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

101. Empagliflozin/metformin - benefit assessment

Empagliflozin/metformin - benefit assessment Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Empagliflozin/Metformin – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 May 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A16-13 Empagliflozin/metformin – Benefit assessment according to §35a (...) Social Code Book V 1 Extract of dossier assessment A16-13 Version 1.0 Empagliflozin/metformin – Benefit assessment acc. to §35a SGB V 30 May 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Empagliflozin/metformin – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 February 2016 Internal Commission No.: A16-13

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

102. [Sitagliptin/metformin - benefit assessment according to õ35a Social Code Book V]

[Sitagliptin/metformin - benefit assessment according to õ35a Social Code Book V] Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-45 [Sitagliptin/metformin - benefit assessment according to §35a Social Code Book V] Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-45 [Sitagliptin/metformin - benefit assessment according to §35a (...) Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag

2017 Health Technology Assessment (HTA) Database.

103. [Saxagliptin / metformin - benefit assessment according to õ 35a Social Code Book V]

[Saxagliptin / metformin - benefit assessment according to õ 35a Social Code Book V] Saxagliptin/Metformin (Diabetes mellitus Typ 2): Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung; Auftrag A16-4 [Saxagliptin / metformin - benefit assessment according to § 35a Social Code Book V] Saxagliptin/Metformin (Diabetes mellitus Typ 2): Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung; Auftrag A16-4 [Saxagliptin / metformin - benefit assessment according (...) to § 35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Saxagliptin/Metformin (Diabetes mellitus Typ 2): Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

2017 Health Technology Assessment (HTA) Database.

104. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. (PubMed)

Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Clomiphene citrate (CC) is generally considered first-line treatment in women with anovulation due to polycystic ovary syndrome (PCOS). Ovulation induction with follicle-stimulating hormone (FSH; gonadotrophins) is second-line treatment for women who do not ovulate or conceive while taking CC. Metformin may increase (...) the effectiveness of ovulation induction with gonadotrophins and may promote safety by preventing multiple pregnancy.To determine the effectiveness and safety of metformin co-treatment during ovulation induction with gonadotrophins with respect to rates of live birth and multiple pregnancy in women with PCOS.We searched the Cochrane Gynaecology and Fertility (CGF) Group specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO and the Cumulative Index

2017 Cochrane

105. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. (PubMed)

Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Recent changes to the U.S. Food and Drug Administration boxed warning for metformin will increase its use in persons with historical contraindications or precautions. Prescribers must understand the clinical outcomes of metformin use in these populations.To synthesize data addressing outcomes of metformin use in populations with type 2 diabetes (...) diabetes regimens that included metformin with those that did not; and 3) reported all-cause mortality, major adverse cardiovascular events, and other outcomes of interest.2 reviewers abstracted data and independently rated study quality and strength of evidence.On the basis of quantitative and qualitative syntheses involving 17 observational studies, metformin use is associated with reduced all-cause mortality in patients with CKD, CHF, or CLD with hepatic impairment, and with fewer heart failure

Full Text available with Trip Pro

2017 Annals of Internal Medicine

106. Metformin Use in Patients With Historical Contraindications (PubMed)

Metformin Use in Patients With Historical Contraindications 28055052 2017 12 08 2018 12 02 1539-3704 166 3 2017 02 07 Annals of internal medicine Ann. Intern. Med. Metformin Use in Patients With Historical Contraindications. 225-226 10.7326/M16-2712 Lipska Kasia J KJ From Yale School of Medicine, New Haven, Connecticut. eng K23 AG048359 AG NIA NIH HHS United States L30 AG045923 AG NIA NIH HHS United States P30 AG021342 AG NIA NIH HHS United States Journal Article Research Support, N.I.H (...) ., Extramural Comment 2017 01 03 United States Ann Intern Med 0372351 0003-4819 0 Hypoglycemic Agents 9100L32L2N Metformin AIM IM Ann Intern Med. 2017 Feb 7;166(3):191-200 28055049 Contraindications Diabetes Mellitus, Type 2 Humans Hypoglycemic Agents Metformin 2017 1 6 6 0 2017 12 9 6 0 2017 1 6 6 0 ppublish 28055052 2595890 10.7326/M16-2712 PMC5334793 NIHMS850043 N Engl J Med. 1998 Jan 22;338(4):265-6 9441244 Ann Intern Med. 2011 May 3;154(9):602-13 21403054 Lancet. 1998 Sep 12;352(9131):854-65 9742977

Full Text available with Trip Pro

2017 Annals of Internal Medicine

107. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions 4 Department of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Metformin Use in Patients with Contraindications or Precautions September 2016 Prepared for: Department of Veterans Affairs Veterans Health Administration Quality Enhancement Research Initiative Health Services Research & Development Service Washington, DC 20420 Prepared by: Evidence-based Synthesis Program (...) Affairs and should not be distributed outside the agency. Metformin Use in Patients with Contraindications or Precautions Evidence-based Synthesis Program i PREFACE The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for four ESP Centers, and each Center has

2017 Veterans Affairs Evidence-based Synthesis Program Reports

109. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline.

Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving (...) of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017 Sep;108(3):426-41. [80 references] This is the current release of the guideline. This guideline meets NGC's 2013 (revised) inclusion criteria. Age Group UMLS Concepts ICD9CM (628.9), (256.4) MSH

2017 National Guideline Clearinghouse (partial archive)

110. Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V

Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Saxagliptin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-33 Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-33 Version 1.0 Saxagliptin/metformin (type 2 diabetes mellitus) 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

111. Role of metformin for ovulation induction in infertile patients with PCOS

Role of metformin for ovulation induction in infertile patients with PCOS Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Metforminalonecomparedwithplaceboincreasestheovulationrateinwomenwithpolycysticovarysyndrome(PCOS)butshouldnot be used as?rst-line therapy for anovulation because oral ovulation (...) induction agents such as clomiphene citrate or letrozole alone are muchmoreeffectiveinincreasingovulation,pregnancy,andlive-birthratesinwomenwithPCOS.Thereisfairevidencethatmetformin alone does not increase rates of miscarriage when stopped at the initiation of pregnancy and insuf?cient evidence that metformin in combinationwithotheragentsusedtoinduceovulationincreaseslive-birthrates.(FertilSteril 2017;108:426–41.2017byAmerican Society for Reproductive Medicine.) Discuss: You can discuss this article

2017 Society for Assisted Reproductive Technology

112. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells (PubMed)

Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder that causes systemic accelerated aging in children. This syndrome is due to a mutation in the LMNA gene that leads to the production of a truncated and toxic form of lamin A called progerin. Because the balance between the A-type lamins is controlled by the RNA-binding protein SRSF1, we have (...) hypothesized that its inhibition may have therapeutic effects for HGPS. For this purpose, we evaluated the antidiabetic drug metformin and demonstrated that 48 h treatment with 5 mmol/l metformin decreases SRSF1 and progerin expression in mesenchymal stem cells derived from HGPS induced pluripotent stem cells (HGPS MSCs). The effect of metformin on progerin was then confirmed in several in vitro models of HGPS, i.e., human primary HGPS fibroblasts, LmnaG609G/G609G mouse fibroblasts and healthy MSCs

Full Text available with Trip Pro

2016 NPJ aging and mechanisms of disease

113. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions Management Briefs eBrief-no116 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no116 -- Health Services Research & Development Management eBrief no. 116 » Issue 116 October 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Metformin Use in Patients with Historical (...) Contraindications or Precautions Metformin is an oral hypoglycemic medication used primarily for treating type 2 diabetes mellitus. Evidence suggests that in addition to improving glycemic control, metformin may be associated with improved all-cause and cardiovascular mortality and decreased risk of some cancers. However, clinicians have traditionally been advised by the U.S. Food and Drug Administration (FDA) to exercise caution in prescribing metformin to individuals with chronic kidney disease (CKD

2016 Veterans Affairs - R&D

114. [Empagliflozin/metformin]

[Empagliflozin/metformin] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47. [Empagliflozin/metformin - addendum to commission A16-13] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 418. 2016 Final publication URL Indexing Status Subject indexing

2016 Health Technology Assessment (HTA) Database.

115. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study)

Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) Gemigliptin is a new dipeptidyl peptidase-IV inhibitor. We investigated the efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes (T2D).A total of 433 T2D patients (...) with a glycosylated haemoglobin (HbA1c) level of 7.5% to 11.0% and a fasting plasma glucose (FPG) concentration <270 mg/dL were randomly assigned to 3 groups: (1) gemigliptin 50 mg qd + metformin 1000 to 2000 mg qd (titrated individually), (2) gemigliptin 50 mg qd, or (3) metformin 1000 to 2000 mg qd. The primary end-point was the change in HbA1c level after 24 weeks. Secondary end-points were the changes in FPG, insulin, proinsulin and C-peptide levels. The percentages of responders who achieved an HbA1c level

Full Text available with Trip Pro

2016 EvidenceUpdates

116. Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function

Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function | European Medicines Agency Search Search Menu Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Press release 14/10/2016 Recommendations for patients with kidney impairment updated in The European Medicines Agency (EMA) has concluded that metformin (...) -containing medicines can now be used in patients with moderately reduced kidney function (GFR [glomerular filtration rate]=30–59 ml/min) for the treatment of type 2 diabetes. The for these medicines will be updated to revise the current contraindication and give information about doses, monitoring and precautions in patients with reduced kidney function. The recommendations are the result of a review by EMA of metformin-containing medicines following concerns that current scientific evidence does

2016 European Medicines Agency - EPARs

117. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. (PubMed)

Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual cancer types has not been presented.We systematically searched research databases, conference abstracts and trial registries for any studies reporting cancer outcomes (...) for individual tumour types in metformin users compared with non-users, and extracted data on patients with early-stage cancer. Studies were assessed for design and quality, and a meta-analysis was conducted to quantify the adjuvant effect of metformin on recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS), to inform future trial design.Of 7670 articles screened, 27 eligible studies were identified comprising 24 178 participants, all enrolled in observational studies

Full Text available with Trip Pro

2016 Annals of oncology : official journal of the European Society for Medical Oncology

118. Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. (PubMed)

Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. Some previous studies have found that continued metformin use is beneficial in the management of polycystic ovary syndrome (PCOS) in pregnant women. A systemic review and meta-analysis were needed to more fully assess the effects of metformin on pregnant PCOS patients.The literature was fully searched using MEDLINE, EMBASE, SCOPUS, and COCHRANE for continued metformin use during pregnancy (...) in women with PCOS. A systematic review and meta-analysis were performed to evaluate the comprehensive effects of continued metformin treatment on pregnancy-related outcomes in these women.Eleven eligible studies out of 127 relevant publications were included in meta-analysis. The rates of early pregnancy loss and preterm delivery were found to be significantly decreased in metformin-treated PCOS women. A non-significant difference was found in fetal abnormality and fetal birth weight between

2016 Clinical and investigative medicine. Médecine clinique et experimentale

119. Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications

Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found (...) Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Metformin taken by obese pregnant women did not reduce their baby's birthweight. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , & . Carolyn A Chiswick 1 , Rebecca M Reynolds 2 , Fiona C Denison 1 , Amanda J

Full Text available with Trip Pro

2016 NIHR HTA programme

120. Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial (PubMed)

Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial To determine whether metformin can achieve glucose control no worse than insulin (noninferiority) without the danger of hypoglycemia (superiority). In addition, to assess whether metformin has any additional effects on lipolysis and inflammation that will enhance burn recovery (superiority).Hyperglycemia and insulin resistance after burn injury (...) are associated with increased morbidity and mortality. Insulin administration improves postburn infections, severity of sepsis, and morbidity, but also causes a 4-5-fold increase in hypoglycemia, which is associated with a 9-fold increase in mortality.Severely burned adult patients with burns over 20% total body surface area (TBSA) burn were prospectively randomized in this Phase II clinical trial to either metformin or insulin (standard of care) treatment. Primary outcomes were glucose levels and incidence

2016 EvidenceUpdates